Wegovy Sign In: What Getting Started Really Involves

What the clinical guidance says about starting semaglutide

The NICE technology appraisal for semaglutide (TA875, published March 2023) sets out clear criteria: Wegovy is recommended for adults with a BMI of 35 or above and at least one weight-related health condition, used for a maximum of two years within a specialist weight management service. Lower BMI thresholds apply for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, typically 2.5 kg/m² less. These aren't arbitrary bureaucratic hurdles; they reflect the population studied in the STEP 1 clinical trial, which found an average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose. The trial results are published in the New England Journal of Medicine and underpin every prescribing decision a clinician makes today.

If <5% of body weight is lost after six months at the maintenance dose, continuing is reviewed. That review happens with your prescriber, not by you alone, which is exactly why a relationship with a named clinician matters from day one, not just at sign-up.

A quick check worth doing before you start: look up any online pharmacy you're considering on the GPhC pharmacy register. It takes under a minute and confirms the pharmacy is legally allowed to dispense prescription medicines in the UK. A GPhC registration number on the website should match the entry you find there.

What 'signing up' looks like on the private route

For people who don't meet NHS criteria, or who don't want to wait, the private route means completing a structured medical consultation (usually online) with a GPhC-registered Independent Prescriber. At nume, a real clinician reads every consultation the same day; your answers go to a prescriber's desk, not to an automated triage system. Photo ID and live weight verification are part of the process, as is a record sent to your GP in line with GPhC guidance.

The consultation covers your current health, any medicines you take, your weight history, and whether semaglutide is suitable for you right now. If it is, treatment is dispatched the same day for orders placed before noon Monday to Friday, and arrives via DPD the next working day in plain, unbranded packaging. You can read more about what that process looks like on our guide to where to buy Wegovy in the UK, which covers both NHS and private options in detail.

Once you're on treatment, the consultation doesn't end. Every repeat order is clinically re-reviewed, dose increases aren't automatic, and evidence of your progress is part of each assessment. That ongoing structure is part of what you're signing up to, not just the first injection.

What changes with the newer 7.2mg pen, and why it matters for new starters

In April 2026 the MHRA approved a dedicated single-dose 7.2mg Wegovy pen, a pre-set weekly injection with a built-in covered needle that locks after use. This approval, confirmed in a GOV.UK announcement on 14 April 2026, extended the maximum maintenance dose for eligible adults with a BMI of 30 or above. Trials at 7.2mg reported average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide considerably.

For anyone signing up to Wegovy now, this matters because the ceiling of what treatment can achieve has shifted. Starting dose remains 0.25mg, titrated upward by your prescriber in roughly four-week steps, the pace is set by tolerability, not impatience. If you're curious whether you'd be a candidate for the higher dose, that's a conversation for the consultation, not something to decide from a website. Our semaglutide overview page covers the full dose ladder in context.

Side effects to know before signing up

Semaglutide's side-effect profile is dominated by gastrointestinal symptoms: nausea, loose stools, constipation, reflux, and occasional vomiting are the most commonly reported. They tend to peak in the days after starting or after a dose increase, then ease as your body adjusts. Fatigue and headaches are less common but not rare.

The NHS medicines page for semaglutide lists the full side-effect profile and flags symptoms that need prompt medical attention, including severe stomach pain that spreads to the back, which can signal pancreatitis. The MHRA issued specific guidance on this in January 2026. Read those details before you start, not once you're mid-treatment.

Wegovy is not suitable during pregnancy, while breastfeeding, or if you're actively trying to conceive. It is not licensed for anyone under 18. People with a history of medullary thyroid carcinoma or certain pancreatic conditions should discuss their history with a prescriber before considering semaglutide, and anyone researching compounded alternatives may also want to read our guide to Sigma semaglutide, which explains how it differs from the licensed product. Our clinical team is available seven days a week for aftercare questions once treatment is underway, details on our contact page.

If you're wondering what progress looks like once you've started, the signs Wegovy is working page walks through what to look for in the early weeks, and if you have concerns about visual changes during treatment, our page on Wegovy and sight loss covers what the current evidence says. When you're ready to take the first step, speak to our prescribers through a free consultation.